DESCRIPTION: This website harnesses results from genome-wide association studies (GWAS), and drug bioactivity data, to prioritize drugs and targets for a given phenotype. Drug Targetor networks are constructed using genetically scored drugs and genes, connected by the type of drug-target or drug-gene interaction
CITATION: Gaspar, H. A., Hübel, C., & Breen, G. (2019). Drug Targetor: a web interface to investigate the human druggome for over 500 phenotypes. Bioinformatics, 35(14), 2515-2517.
GREP
SHORT NAME: GREP
FULL NAME:Genome for REPositioning drugs
YEAR: 2019
DESCRIPTION: GREP can quantify an enrichment of the user-defined set of genes in the target of clinical indication categories and capture potentially repositionable drugs targeting the gene set. Both can be run in a few seconds!
CITATION: Sakaue, S., & Okada, Y. (2019). GREP: genome for REPositioning drugs. Bioinformatics, 35(19), 3821-3823.
Open Targets Genetics
FULL NAME:Open Targets Genetics
SHORT NAME:Open Targets Genetics
YEAR: 2021
DESCRIPTION: Open Targets Genetics is a comprehensive tool highlighting variant-centric statistical evidence to allow both prioritisation of candidate causal variants at trait-associated loci and identification of potential drug targets.
CITATION: Ghoussaini, M., Mountjoy, E., Carmona, M., Peat, G., Schmidt, E. M., Hercules, A., ... & Dunham, I. (2021). Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. Nucleic acids research, 49(D1), D1311-D1320.
CITATION:Mountjoy, E., Schmidt, E. M., Carmona, M., Schwartzentruber, J., Peat, G., Miranda, A., ... & Ghoussaini, M. (2021). An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. Nature Genetics, 53(11), 1527-1533.
Priority index
FULL NAME:Priority index
SHORT NAME:Priority index
YEAR: 2019
DESCRIPTION: A Comprehensive Resource for Genetic Targets in Immune-Mediated Disease
CITATION:Fang, H., De Wolf, H., Knezevic, B., Burnham, K. L., Osgood, J., Sanniti, A., ... & Knight, J. C. (2019). A genetics-led approach defines the drug target landscape of 30 immune-related traits. Nature genetics, 51(7), 1082-1091.
Trans-Phar
FULL NAME:integration of Transcriptome-wide association study and Pharmacological database
SHORT NAME:Trans-Phar
YEAR: 2021
DESCRIPTION: This software achieves in silico screening of chemical compounds, which have inverse effects in expression profiles compared with genetically regulated gene expression of common diseases, from large-scale pharmacological database (Connectivity Map [CMap] L1000 library).
CITATION: Konuma, T., Ogawa, K., & Okada, Y. (2021). Integration of genetically regulated gene expression and pharmacological library provides therapeutic drug candidates. Human Molecular Genetics, 30(3-4), 294-304.
Hypothesis: "Compounds, which have inverse effects in gene expression profiles when compared with GREx from common diseases, could be detected as potential drug candidates that are effective for disease treatment"
PS4DR
FULL NAME:Pathway Signatures for Drug Repositioning
SHORT NAME:PS4DR
YEAR: 2020
DESCRIPTION: This package comprises a modular workflow designed to identify drug repositioning candidates using multi-omics data sets. A schematic figure of the workflow is presented below. The R scripts necessary to run the MSDRP pipeline are located in the R directory.
CITATION: Emon, M. A., Domingo-Fernández, D., Hoyt, C. T., & Hofmann-Apitius, M. (2020). PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures. BMC bioinformatics, 21(1), 1-21.
PES
FULL NAME:Pharmagenic_enrichment_score
SHORT NAME: PES
YEAR: 2020
DESCRIPTION: a framework to quantify an individual’s common variant enrichment in clinically actionable systems responsive to existing drugs.
CITATION: Reay, W. R., Atkins, J. R., Carr, V. J., Green, M. J., & Cairns, M. J. (2020). Pharmacological enrichment of polygenic risk for precision medicine in complex disorders. Scientific reports, 10(1), 1-12.
Reviews&Key_papers
A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis
YEAR: 2022
DESCRIPTION: a practical guideline for genomics-driven drug discovery for cross-population meta-analysis, as lessons from the Global Biobank Meta-analysis Initiative (GBMI)
CITATION: Namba, S., Konuma, T., Wu, K. H., Zhou, W., Okada, Y., & Global Biobank Meta-analysis Initiative. (2022). A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. Cell Genomics, 2(10), 100190.